Safety of PD-1 Inhibitors in Squamous Non-Small Cell Lung Cancer
2 意见
• 07/14/23
0
0
嵌入
The panelists, Benjamin Levy, MD; Edward S. Kim, MD, FACP; and Paul K. Paik, MD, identify patients with squamous non-small cell lung cancer who may benefit from immune checkpoint inhibitors and the management of any related toxicity.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论